Date | Time | Source | Announcement |
---|---|---|---|
06 Mar 2008 | 07:01 AM | Research Update | |
06 Mar 2008 | 07:00 AM | Interim Results | |
04 Feb 2008 | 07:00 AM | Notice of Results | |
12 Dec 2007 | 07:01 AM | Genentech Agreement | |
30 Nov 2007 | 07:00 AM | Total Voting Rights | |
19 Nov 2007 | 07:00 AM | Director/PDMR Shareholding | |
16 Nov 2007 | 07:01 AM | Board Appointment | |
15 Nov 2007 | 03:07 PM | Placing of Shares | |
15 Nov 2007 | 12:59 PM | AGM Statement | |
31 Oct 2007 | 03:58 PM | Total Voting Rights | |
26 Oct 2007 | 04:35 PM | Director/PDMR Shareholding | |
24 Oct 2007 | 12:24 PM | Placing of shares | |
22 Oct 2007 | 07:01 AM | Fundraising | |
16 Oct 2007 | 04:33 PM | Annual Report and AGM notice | |
08 Oct 2007 | 11:01 AM | Holding(s) in Company | |
02 Oct 2007 | 07:01 AM | Research Update | |
02 Oct 2007 | 07:01 AM | Preliminary Results | |
21 Sep 2007 | 07:01 AM | Directorate Change | |
13 Sep 2007 | 09:42 AM | Notice of Results | |
16 Aug 2007 | 07:00 AM | Disclosure of Information | |
30 Jul 2007 | 07:02 AM | Extention of Collaboration | |
18 Jun 2007 | 12:34 PM | Directorate Change | |
15 May 2007 | 07:00 AM | Cancer Program Update | |
06 Feb 2007 | 07:01 AM | Research Programme Update | |
06 Feb 2007 | 07:00 AM | Interim Results | |
31 Jan 2007 | 11:08 AM | Total Voting Rights | |
22 Jan 2007 | 07:00 AM | Collaboration with J&J | |
12 Jan 2007 | 07:00 AM | Notice of Results & Update | |
08 Jan 2007 | 07:00 AM | New Investment in Sareum | |
18 Dec 2006 | 04:39 PM | Total Voting Rights | |
20 Nov 2006 | 07:00 AM | Agreement with Genentech | |
30 Oct 2006 | 04:23 PM | Issue of Equity | |
19 Oct 2006 | 05:40 PM | Board Change | |
19 Oct 2006 | 10:43 AM | AGM Statement | |
09 Oct 2006 | 07:00 AM | Significant Collaboration | |
26 Sep 2006 | 07:00 AM | Roche Cancer Collaboration | |
25 Sep 2006 | 04:37 PM | Posting of accounts | |
04 Sep 2006 | 07:01 AM | Preliminary Results | |
31 Aug 2006 | 07:00 AM | Cancer Drug Collaboration | |
15 Aug 2006 | 07:00 AM | Collaboration with Lundbeck | |
13 Jul 2006 | 07:00 AM | Extension of Collaboration | |
20 Jun 2006 | 07:01 AM | Collaboration with Sirtris | |
14 Jun 2006 | 09:45 AM | Holding(s) in Company | |
08 Jun 2006 | 07:00 AM | Success with Schering AG | |
28 Mar 2006 | 05:38 PM | Holding(s) in Company | |
08 Mar 2006 | 01:08 PM | Holding(s) in Company | |
23 Feb 2006 | 07:00 AM | Interim Results | |
16 Feb 2006 | 12:30 PM | Exercise of option | |
16 Feb 2006 | 10:51 AM | Notice of Results | |
13 Feb 2006 | 04:26 PM | Exercise of option |
Sareum Holdings Plc (Sareum) is a clinical-stage drug discovery and development company that produces targeted small-molecule therapeutics for treating cancer and autoimmune diseases.
The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor Library (SKIL). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (checkpoint kinase 1), Aurora+FLT3 kinase, Autoimmune-TYK2/JAK1 kinases, and Cancer-TYK2/JAK1 kinases. Sareum's Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Cambridge, the UK.
SAR share price listed on AIM in 2004 under the ticker SAR.